SynthesisBMC neurology2025
Identification of the efficacy and safety of apomorphine in the treatment of Parkinson's disease via meta-analysis.
Synthesis in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe majority of Parkinson's disease (PD) patients experience motor fluctuations and dyskinesias as the disease progresses. Apomorphine has been used as an acute treatment for off episodes in PD in recent years. However, conclusions from clinical studies regarding the efficacy and safety of apomorphine have been inconsistent, particularly prior to the publication of larger pivotal trials.
objectivesTo systematically evaluate the efficacy and safety of apomorphine in PD patients, a meta-analysis of randomized controlled trials (RCTs) and single-armed studies were performed.
methodsPubMed, Web of Science, Embase, and Cochrane databases were searched to identify all related studies. Outcomes of interest were changes in Parkinson's Disease Rating Scale Part III (UPDRS-III) scores, ON and OFF time, and adverse events (AES).
resultsIn this meta-analysis, 20 clinical studies were included (n = 1262 patients): seventeen RCTs, and three single-armed studies. The pooled results from RCTs indicate that apomorphine treatment significantly improved patients' motor function compared to placebo. Specifically, there was a mean difference (MD) of -12.28 (95% CI: [-17.98, -6.59]) in UPDRS-III scores. Patients treated with apomorphine experienced a reduced off time (MD = -10.70, 95% CI: [-20.33, -1.06]), indicating a shorter duration of the "off" state. Furthermore, the combined results indicated a conversion rate from off to on state in PD patients treated with apomorphine of 0.79 (95% CI 0.67-0.89). In terms of safety analyses from single-armed studies, apomorphine treatment was associated with several AES, including nausea, drowsiness, vomiting, dizziness, and excessive sweating. However, the findings suggest that the incidence of AES was relatively low during treatment with apomorphine.
conclusionThe meta-analysis results indicate that apomorphine effectively improves dyskinesia and motor fluctuations in patients with PD. Furthermore, the incidence of AES was relatively low during treatment with apomorphine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.